The Fight Against Cancer: Neoantigens, Tumor Escape and the Tumor Microenvironment A conversation with JOHN WEST, CEO of Personalis, Inc. in Menlo, Park, California Nature, October 26, 2017 Tumours may be initiated by mutations in their driver genes, but their clinical outcomes are strongly influenced by the battle between [...]
Getting cancer vaccines right: Key challenges and solutions for neoantigen identification A conversation with Richard Chen, MD, CSO of Personalis, Inc. in Menlo, Park, California FierceBiotech, June 26, 2017 The promise of neoantigen-based cancer vaccines Neoantigen-based cancer vaccines represent new, truly personalized therapeutic approaches to treating cancer. The development of [...]
Genomics Solutions for Neoantigen Based Cancer Therapies High quality, comprehensive genomic data and analytics for personalized cancer therapy development Enabling Truly Personalized Neoantigen Based Cancer Therapies The first step of developing personalized cancer therapeutics is the identification of patient-specific neoantigens. With ImmunoID NeXT™, our partners can utilize our proprietary [...]
2017 AACR: Accurately Identifying Neoantigens Utilizing Both DNA and RNA Somatic Variants in an Enhanced Platform
The identification of neoantigens is a crucial step in the development of neoantigen-based personalized cancer vaccines and other immunotherapies.
2017 AACR: Supporting Neoantigen Identification for Personalized Cancer Vaccines Through Analytical Validation of an Augmented Content Enhanced (ACE) Exome
The identification of neoantigens has become a critical step in the development of neoantigenbased personalized cancer vaccines and other immunotherapy applications.
2017 AACR: Supporting Neoantigen Identification for Personalized Cancer Vaccines Through Analytical Validation of an Augmented Content Enhanced (ACE) Transcriptome
Neoantigen identification, or the detection of tumor-specific variants, is a critical step inpersonalized cancer vaccine development.
GenomeWeb: Comprehensive Tumor Characterization for Immuno Oncology, Clinical Trials, and Cancer Research This GenomeWeb seminar outlines a targeted enrichment technology to improve next-generation sequencing assays for cancer research and clinical applications. Presenters: Richard Chen, MD and Michael James Clark, PhD More Info: NGS is increasingly being used to support cancer clinical trials, translational [...]
Augmented Exome and Transcriptome Sequencing for Neoantigen Identification in Immuno-Oncology White Paper: Augmented Exome and Transcriptome Sequencing for Neoantigen Identification in Immuno-Oncology
Tumor Characterization Solutions for Clinical Trials, Cancer Research & Immuno-Oncology This presentation covers comprehensive tumor characterization solutions for clinical trials, cancer research and immune-oncology, including: specific challenges in sequencing and analyzing tumors for neoantigen identification; key differentiators of the ACE ImmunoID as compared to standard NGS offerings; and a review of the technical [...]
NGS Best Practices for Developing Personalized Neoantigen Vaccines Precision medicine strategies have changed how the industry is approaching the development of cancer treatment vaccines, from targeting tumor-specific mutations to harnessing the power of the immune system. Advances in immuno-oncology research and next-generation sequencing (NGS) technologies has led to the discovery of a promising [...]